In the past year, Don has helped lead the company’s efforts to enhance diversity in clinical trials participation, including shepherding development of an implementation plan specific to PhRMA’s revised clinical trials principles. Don has also represented Astellas in discussions on the reauthorization of the Prescription Drug User Fee Act (PDUFA), working to encourage an efficient process with provisions that advance innovative drug development tools and approaches that can help safely expedite patient access to new medicines. Don serves as the executive sponsor of Astellas’ Stellar Women Employee Impact Group.